1027 related articles for article (PubMed ID: 31439588)
21. Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.
Xu H; Yang G; Yang L; Yang Y; Ma D; Li J; Hao X; Xing P; Wang Y
Thorac Cancer; 2019 May; 10(5):1096-1102. PubMed ID: 30920172
[TBL] [Abstract][Full Text] [Related]
22. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in
Dietz S; Christopoulos P; Gu L; Volckmar AL; Endris V; Yuan Z; Ogrodnik SJ; Zemojtel T; Heussel CP; Schneider MA; Meister M; Muley T; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31753813
[TBL] [Abstract][Full Text] [Related]
23. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
[TBL] [Abstract][Full Text] [Related]
24. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
25.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
26. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
[TBL] [Abstract][Full Text] [Related]
28. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
29. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Makimoto G; Ohashi K; Tomida S; Nishii K; Matsubara T; Kayatani H; Higo H; Ninomiya K; Sato A; Watanabe H; Kano H; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Toyooka S; Takata M; Maeda Y; Kiura K
J Thorac Oncol; 2019 Nov; 14(11):2009-2018. PubMed ID: 31374369
[TBL] [Abstract][Full Text] [Related]
30. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
[TBL] [Abstract][Full Text] [Related]
31. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Dagogo-Jack I; Yoda S; Lennerz JK; Langenbucher A; Lin JJ; Rooney MM; Prutisto-Chang K; Oh A; Adams NA; Yeap BY; Chin E; Do A; Marble HD; Stevens SE; Digumarthy SR; Saxena A; Nagy RJ; Benes CH; Azzoli CG; Lawrence MS; Gainor JF; Shaw AT; Hata AN
Clin Cancer Res; 2020 Jun; 26(11):2535-2545. PubMed ID: 32086345
[TBL] [Abstract][Full Text] [Related]
32. Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.
Liu C; Liu C; Liao J; Yin JC; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Shao Y; Wang J
Lung Cancer; 2022 Sep; 171():18-25. PubMed ID: 35870258
[TBL] [Abstract][Full Text] [Related]
33. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
35. Lorlatinib for the treatment of
Choo JR; Soo RA
Expert Rev Anticancer Ther; 2020 Apr; 20(4):233-240. PubMed ID: 32186215
[No Abstract] [Full Text] [Related]
36. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
[TBL] [Abstract][Full Text] [Related]
37. Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K; Seto Y; Okada K; Uematsu S; Uchibori K; Tsukahara M; Oh-Hara T; Fujita N; Yanagitani N; Nishio M; Okubo K; Katayama R
Thorac Cancer; 2020 Mar; 11(3):581-587. PubMed ID: 31943796
[TBL] [Abstract][Full Text] [Related]
38. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
39. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
[TBL] [Abstract][Full Text] [Related]
40. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma.
He W; Xu D; Wang Z; Wu H; Xiang X; Tang B; Jiang W; Cui Y; Wang H; Jiang N; Sun Y; Chen Y; Li S; Hou M; Zhang Y; Wang L; Ke ZF
J Transl Med; 2019 Jan; 17(1):32. PubMed ID: 30658713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]